CD33-like protein
AssigneeHuman Genome Sciences, Inc.
InventorsJian Ni, Reiner L. Gentz, Craig A. Rosen
Life of this patent
Estimating the term…
Abstract
The present invention concerns a novel CD33-like protein. In particular, isolated nucleic acid molecules are provided encoding the CD33-like protein. Recombinant CD33-like polypeptides are also provided as are recombinant vectors and host cells. The invention further provides methods useful during tumor or inflammatory disease diagnosis or prognosis and therapeutic treatments targeting cells expressing CD33-like polypeptides.
Claims13
An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of:
- (a) a nucleotide sequence encoding a polypeptide comprising amino acids from about −15 to about 536 in SEQ ID NO:2;
- (b) a nucleotide sequence encoding a polypeptide comprising amino acids from about −14 to about 536 in SEQ ID NO:2;
- (c) a nucleotide sequence encoding a polypeptide comprising amino acids from about 1 to about 536 in SEQ ID NO:2;
- (d) a nucleotide sequence encoding a polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 97521;
- (e) a nucleotide sequence encoding the mature CD33-like polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 97521;
- (f) a nucleotide sequence encoding the CD33-like polypeptide extracellular domain;
- (g) a nucleotide sequence encoding the CD33-like polypeptide transmembrane domain;
- (h) a nucleotide sequence encoding the CD33-like polypeptide intracellular domain;
- (i) a nucleotide sequence encoding the CD33-like polypeptide receptor extracellular and intracellular domains with all or part of the transmembrane domain deleted;
- and
- a nucleotide sequence complementary to any of the nucleotide sequences in (a), (b), (c), (d), (e), (f), (g), (h), or (i).
An isolated CD33-like polypeptide having an amino acid sequence at least 95% identical to a sequence selected from the group consisting of:
- (a) amino acids from about −15 to about 536 in SEQ ID NO:2;
- (b) amino acids from about −14 to about 536 in SEQ ID NO:2;
- (c) amino acids from about 1 to about 536 in SEQ ID NO:2;
- (d) the amino acid sequence of the CD33-like polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 97521;
- (e) the amino acid sequence of the mature CD33-like polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No.97521;
- (f) the amino acid sequence of the CD33-like polypeptide extracellular domain;
- (g) the amino acid sequence of the CD33-like polypeptide transmembrane domain;
- (h) the amino acid sequence of the CD33-like polypeptide intracellular domain;
- (i) the amino acid sequence of the CD33-like polypeptide extracellular and intracellular domains with all or part of the transmembrane domain deleted;
- and
- (j) the amino acid sequence of an epitope-bearing portion of any one of the polypeptides of (a), (b), (c), (d), (e), (f), (g), (h), or (i).
An isolated-nucleic acid molecule comprising a polynucleotide encoding a CD33-like polypeptide wherein, except for at least one conservative amino acid substitution, said polypeptide has a sequence selected from the group consisting of:
- (a) a nucleotide sequence encoding a polypeptide comprising amino acids from about −15 to about 536 in SEQ ID NO:2;
- (b) a nucleotide sequence encoding a polypeptide comprising amino acids from about −14 to about 536 in SEQ ID NO:2;
- (c) a nucleotide sequence encoding a polypeptide comprising amino acids from about 1 to about 536 in SEQ ID NO:2;
- (d) a nucleotide sequence encoding a polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 97521;
- (e) a nucleotide sequence encoding the mature CD33-like polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 97521;
- (f) a nucleotide sequence encoding the CD33-like polypeptide extracellular domain;
- (g) a nucleotide sequence encoding the CD33-like polypeptide transmembrane domain;
- (h) a nucleotide sequence encoding the CD3 3-like polypeptide intracellular domain;
- (i) a nucleotide sequence encoding the CD33-like polypeptide receptor extracellular and intracellular domains with all or part of the transmembrane domain deleted;
- and
- (j) a nucleotide sequence complementary to any of the nucleotide sequences in (a), (b), (c), (d), (e), (f), (g), (h), or (i).
An isolated CD33-like polypeptide wherein, except for at least one conservative amino acid substitution, said polypeptide has a sequence selected from the group consisting of:
- (a) amino acids from about −15 to about 536 in SEQ ID NO:2;
- (b) amino acids from about −14 to about 536 in SEQ ID NO:2;
- (c) amino acids from about 1 to about 536 in SEQ ID NO:2;
- (d) the amino acid sequence of the CD33-like polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 97521;
- (e) the amino acid sequence of the mature CD33-like polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No.97521;
- (f) the amino acid sequence of the CD33-like polypeptide extracellular domain;
- (g) the amino acid sequence of the CD33-like polypeptide transmembrane domain;
- (h) the amino acid sequence of the CD33-like polypeptide intracellular domain;
- (i) the amino acid sequence of the CD33-like polypeptide extracellular and intracellular domains with all or part of the transmembrane domain deleted;
- and
- (j) the amino acid sequence of an epitope-bearing portion of any one of the polypeptides of (a), (b), (c), (d), (e), (f), (g), (h), or (i).
An isolated nucleic acid molecule comprising a polynucleotide having a sequence at least 95% identical to a sequence selected from the group consisting of:
- (a) the nucleotide sequence of clone HTOBA14R (SEQ ID NO:11);
- and
- (b) the nucleotide sequence of a portion of the sequence shown in SEQ ID NO:1 wherein said portion comprises at least 50 contiguous nucleotides from nucleotide 1 to nucleotide 1898;
- and
- (c) a nucleotide sequence complementary to any of the nucleotide sequences in (a) or (b) above.
Dependencies are inferred from the claim text.